JY
ANVS icon

Jeff Yass’s Annovis Bio ANVS Stock Holding History

Jeff Yass’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Sell
146,804
-71,532
-33% -$139K ﹤0.01% 11263
2026
Q1 		$487K Sell
218,336
-84,951
-28% -$233K ﹤0.01% 9740
2025
Q4 		$1.05M Buy
303,287
+84,866
+39% +$255K ﹤0.01% 7073
2025
Q3 		$452K Buy
218,421
+53,863
+33% +$135K ﹤0.01% 9191
2025
Q2 		$357K Buy
164,558
+36,853
+29% +$72.7K ﹤0.01% 9951
2025
Q1 		$192K Buy
127,705
+72,393
+131% +$222K ﹤0.01% 10978
2024
Q4 		$278K Buy
55,312
+23,792
+75% +$172K ﹤0.01% 9998
2024
Q3 		$254K Buy
+31,520
New +$295K ﹤0.01% 9970
2024
Q2 		– Sell
-72,602
Closed -$588K – 11969
2024
Q1 		$864K Buy
72,602
+56,830
+360% +$620K ﹤0.01% 7238
2023
Q4 		$295K Buy
+15,772
New +$140K ﹤0.01% 9882
2023
Q2 		– Sell
-13,800
Closed -$213K – 11996
2023
Q1 		$213K Buy
+13,800
New +$223K ﹤0.01% 10467

Other funds holding ANVS

EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jeff Yass's ANVS Position: Q2 2026 in Review

Jeff Yass reduced its Annovis Bio (ANVS) stake by 33% in Q2 2026, selling an estimated $139K and leaving 146,804 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #11263.

Jeff Yass first reported a position in ANVS in Q1 2023 and has held it in 11 quarters since. The position peaked at $1.05M in Q4 2025. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

  • Jeff Yass held 146,804 shares of Annovis Bio worth $273K as of Q2 2026.
  • Jeff Yass sold 71,532 Annovis Bio shares in Q2 2026, an estimated $139K.
  • Annovis Bio made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11263 holding.
  • Jeff Yass first reported a position in Annovis Bio in Q1 2023 and has held it in 11 quarters since.
  • Jeff Yass's Annovis Bio position peaked at $1.05M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.